Cogent Biosciences rises after Wainwright raises PT
ReutersJul 8, 2025 4:26 PM
Shares of drug developer Cogent Biosciences COGT.O up 5.4% at $9.85
H.C. Wainwright raises COGT's PT to $22 from $12
COGT said on Monday its drug, bezuclastinib, showed a statistically significant reduction in symptoms in patients with mastocytosis, a type of blood disorder
Wainwright says raised probability of approval for bezuclastinib in NonAdvSM to 95% from the prior 60%
Consider 2025 a landmark year for COGN, which could make it an attractive M&A target as well, brokerage says
Up to last close, stock up 19.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
How to View Trump’s Nomination of Kevin Warsh?
TradingKey - On January 30, 2026, U.S. President Trump officially announced the nomination of former Federal Reserve Governor Kevin Warsh to succeed Jerome Powell as the next Chair of the Federal Reserve. This decision rapidly drew significant attention from markets and the public. So, why did Warsh stand out among the numerous candidates?TradingKey
2 hours ago
Should You Buy Berkshire Hathaway Post-Warren Buffett? What's Warren Buffett's Advice for 2026 Investment?
Berkshire built up a hoard of cash through 2025, accumulating nearly $400 billion—more than it had ever held before. That was by design. Berkshire, instead of joining the artificial intelligence rally that led the headlines, put the cash into short-term U.S. Treasuries with about 3.6% yields.TradingKey
6 hours ago
Digital Asset Rotation: Navigating Market Volatility With the Best Cheap Cryptos for 2026
Navigate the 2026 crypto rotation: Analyze the best cheap cryptos like Solana, Chainlink, and XRP amid Bitcoin’s volatility. Discover top picks for utility and long-term gains.TradingKey
18 hours ago
